# Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
**Date:** 2026-02-13 01:15:00
**Company:** Novartis AG
**Ticker:** NVS
**Source URL:** https://www.globenewswire.com/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html
---
[Accessibility: Skip TopNav](https://www.globenewswire.com/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html#maincontainer)
[](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [Services](https://www.globenewswire.com/services)
- [Contact Us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- English
[Sign In](https://www.globenewswire.com/home/signin) [Register](https://portal.notified.com/en/registration)
# [](https://novartis.com/)
# Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
February 13, 2026 01:15 ET\| Source:
[Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)FollowNovartis Pharma AG
* * *
Share
- * * *
- _In ALIGN study, Vanrafia (atrasentan) showed positive difference_ _in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended_ _1_
- _Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors_ _1_
- _Vanrafia received accelerated approval in U.S. and China for reduction of proteinuria in adults with IgAN in 2025; Novartis plans to submit for traditional approval in 2026_ _2_
**Basel, February 13, 2026**– Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment1.
Clinically meaningful results were observed with Vanrafia compared to placebo in eGFR change from baseline at the end of study treatment at Week 132, and in the prespecified exploratory group of patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1. At the end of treatment at Week 132, the eGFR change from baseline compared to placebo was 2.59 ml/min/1.73 m2 (nominal 2- sided p = 0.039)1.
“Progressive and complex diseases such as IgAN present an urgent need for medicines that can target the different drivers of the disease. Vanrafia can be seamlessly integrated into patients’ existing treatment plans, with a consistent safety profile,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal & Metabolic Development Unit, Novartis. “We are pleased with today’s Phase III ALIGN results, which add to the growing evidence of Vanrafia as a potential foundational therapy to slow kidney function decline.”
ALIGN provides the longest follow-up period in pivotal Phase III studies for IgAN3. Safety was consistent with previous findings1.
Alongside Vanrafia, Novartis continues to advance its multi-asset IgAN portfolio, which also includes Fabhalta® (iptacopan) and investigational compound zigakibart.
**About IgAN**
IgAN is a progressive autoimmune kidney disease with approximately 25 per million people newly diagnosed worldwide each year4. IgAN is highly debilitating as it leads to glomerular inflammation (when the small filters in the kidneys are inflamed), proteinuria (excess protein in urine), and a gradual decline in eGFR5. Up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or kidney transplantation as part of long-term disease management5-7.
Furthermore, people living with IgAN often face mental, social, and economic challenges5-8. Supportive care has not addressed the underlying causes of the disease and often fails to slow disease progression, reinforcing the need for more targeted therapies for IgAN4-9.
**About Vanrafia** **®** **(atrasentan)**
Vanrafia (atrasentan) is a potent and highly selective endothelin A (ETA) receptor antagonist, which is part of the endothelin system, a key system involved in the progression of IgAN10-13.
Vanrafia is the first and only selective ETA receptor antagonist approved for primary IgAN, a once-daily, oral treatment and can be seamlessly added to, or used alongside, existing supportive care (e.g. renin-angiotensin system (RAS) inhibitor with or without SGLT2 inhibitor) without the need for titration2. Vanrafia does not require a Risk Evaluation and Mitigation Strategy (REMS) program. Because some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure, clinicians should obtain liver enzyme testing before initiating Vanrafia and during treatment when clinically indicated. Vanrafia may cause serious birth defects2.
**About ALIGN**
The ALIGN study ( [NCT04573478](https://clinicaltrials.gov/study/NCT04573478 "NCT04573478")) is a global, randomized, multicenter, double-blind, placebo-controlled Phase III clinical trial comparing the efficacy and safety of Vanrafia versus placebo in patients with IgAN at risk of progressive loss of kidney function1-3. In total, 340 patients with biopsy-proven IgAN with baseline total proteinuria ≥1 g/day despite optimized RAS inhibitor treatment were randomized to receive once-daily, oral Vanrafia (0.75 mg) or placebo for approximately 132 weeks1,11. Patients continue receiving a maximally tolerated and stable dose of a RAS inhibitor as supportive care1,11. An additional cohort of 64 patients receiving an SGLT2 inhibitor in addition to RAS inhibitor for at least 12 weeks was also enrolled1,11. The primary efficacy endpoint for the interim analysis (in 270 patients) was change in proteinuria, as measured by 24-hour urine protein-to-creatinine ratio (UPCR) from baseline to 36 weeks1,3,11. The key secondary endpoint for the final analysis is the change from baseline to 136 weeks in kidney function as measured by eGFR. Other secondary efficacy endpoints as well as safety and tolerability are also assessed1-3.
**Novartis commitment to kidney diseases**
Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need.
Historically, these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our portfolio targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms - whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians and policymakers, we aim to raise awareness, accelerate diagnosis, and get patients the right care, sooner.
**Disclaimer**
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
**About Novartis**
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at [**https://www.novartis.com**](https://www.novartis.com/ "") and connect with us on [**LinkedIn**](https://www.linkedin.com/company/novartis/ ""), [**Facebook**](https://www.facebook.com/novartis/ ""), [**X/Twitter**](https://twitter.com/Novartis "") and [**Instagram**](https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ "").
**References**
01. Novartis. Data on file.
02. Novartis Pharmaceuticals Corporation. Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN). Available at: [https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan](https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan ""). Accessed February 2026.
03. ClinicalTrials.gov. NCT04573478. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function. Available at [https://clinicaltrials.gov/study/NCT04573478](https://clinicaltrials.gov/study/NCT04573478 ""). Accessed February 2026.
04. Cheung C, Barratt J. The rapidly changing treatment landscape of IgA nephropathy. _Semin Nephrol._ 2025;44:151573.
05. Kwon CS, Daniele P, Forsythe A et al. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. _J Health Econ Outcomes Res._ 2021;8:36–45.
06. Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgAN. _Clin J Am Soc Nephrol._ 2023;18:727–8.
07. Mohd R, Mohammad Kazmin NE, Abdul Cader R, et al. Long-term outcome of immunoglobulin A (IgA) nephropathy: a single center experience. _PLoS One_. 2021;16:e0249592.
08. National Kidney Foundation. The voice of the patient (2020). Available at: [https://igan.org/wp-content/uploads/2021/01/VOP\_IgAN\_12-7-20\_\_FNL.pdf](https://igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf ""). Accessed February 2026.
09. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. _Kidney Int_. 2021;100:S1–276.
10. Barratt J, Kim SG, Inker LA et al. AFFINITY study: 1-year results of atrasentan in IgAN. _J Am Soc Nephrol._ 2024;35(Suppl):720. Abstract FR-P0855.
11. Heerspink HJL, Jardine M, Kohan DE et al. Atrasentan in patients with IgAN. _N Engl J Med._ 2025;392:544–54.
12. Heerspink HJL, Jardine M, Kohan DE et al. Study design and baseline characteristics of ALIGN, a randomized controlled study of atrasentan in patients with IgAN. _Kidney Int Rep._ 2024;10:217–26.
13. Kohan DE, Barratt J, Heerspink HJL et al. Targeting the endothelin A receptor in IgAN. _Kidney Int Rep._ 2023;8:2198–210.
\# # #
| |
| --- |
| **Novartis Media Relations**<br>E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com "media.relations@novartis.com") |
| |
| **Novartis Investor Relations**<br>Central investor relations line: +41 61 324 7944<br>E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com "investor.relations@novartis.com") |
* * *
## Tags
[Media Release](https://www.globenewswire.com/en/search/tag/media%2520release "Media Release")[Clinical Trials](https://www.globenewswire.com/en/search/tag/clinical%2520trials "Clinical Trials")[Reimagine Medicine](https://www.globenewswire.com/en/search/tag/reimagine%2520medicine "Reimagine Medicine")[Diseases](https://www.globenewswire.com/en/search/tag/diseases "Diseases")
### Attachments
[](https://ml-eu.globenewswire.com/Resource/Download/d3bccfbc-0c27-4062-b55c-10e2a4a3e771) Media release (PDF)...
GlobeNewswire
Company ProfileNovartis Pharma AGIndustry: PharmaceuticalsWebsite:
[https://novartis.com](https://novartis.com/)
Press Release Actions
- [Print](https://www.globenewswire.com/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html?print=1)
- [Download PDF](https://www.globenewswire.com/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html?pdf=1)
- [Subscribe via RSS](https://www.globenewswire.com/rssfeed/organization/ApPC3aRBom1jeiovES24_w==)
- [Subscribe via ATOM](https://www.globenewswire.com/atomfeed/organization/ApPC3aRBom1jeiovES24_w==)
- [Javascript](https://www.globenewswire.com/JSWidget/organization/ZF_gxTt0cUPtQANRyd9wjQ%3d%3d)
## Recommended Reading
- February 27, 2026 09:00 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)
[Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy](https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html)
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks...
[Read More](https://www.globenewswire.com/news-release/2026/02/27/3246557/0/en/Novartis-successfully-completes-acquisition-of-Avidity-Biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-xRNA-strategy.html)
- February 27, 2026 06:29 ET\|Source: [Novartis Pharma AG](https://www.globenewswire.com/en/search/organization/Novartis%2520Pharma%2520%2520AG)
[Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)](https://www.globenewswire.com/news-release/2026/02/27/3246401/0/en/Novartis-receives-positive-CHMP-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-CSU.html)
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with...
[Read More](https://www.globenewswire.com/news-release/2026/02/27/3246401/0/en/Novartis-receives-positive-CHMP-opinion-for-remibrutinib-in-chronic-spontaneous-urticaria-CSU.html)
[View More News](https://www.globenewswire.com/en/newsroom)
## Explore
Previous
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html)
March 03, 2026 16:18 ET
[Kraken Robotics Announces Signing of Strategic Acq...](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html "Kraken Robotics...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html)
March 03, 2026 16:05 ET
[Coherent Executives to Showcase Thought Leadership...](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html "Coherent Executives...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html)
March 03, 2026 16:18 ET
[Kraken Robotics Announces Signing of Strategic Acq...](https://www.globenewswire.com/news-release/2026/03/03/3248950/0/en/Kraken-Robotics-Announces-Signing-of-Strategic-Acquisition-to-Expand-Global-Maritime-Capabilities.html "Kraken Robotics...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html)
March 03, 2026 16:05 ET
[Coherent Executives to Showcase Thought Leadership...](https://www.globenewswire.com/news-release/2026/03/03/3248903/0/en/Coherent-Executives-to-Showcase-Thought-Leadership-at-OFC-CTO-Julie-Eng-to-Deliver-the-Plenary-Session.html "Coherent Executives...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html)
March 03, 2026 15:57 ET
[Toll Brothers Announces Final Opportunity to Own a...](https://www.globenewswire.com/news-release/2026/03/03/3248885/0/en/Toll-Brothers-Announces-Final-Opportunity-to-Own-a-Luxury-Townhome-at-Mira-Vista-in-San-Diego-California.html "Toll Brothers...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html)
March 03, 2026 15:20 ET
[Witte Museum Brings '90s Nostalgia to Life with Th...](https://www.globenewswire.com/news-release/2026/03/03/3248862/0/en/Witte-Museum-Brings-90s-Nostalgia-to-Life-with-The-Robot-Zoo.html "Witte Museum Brings...")
[](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html)
March 03, 2026 15:18 ET
[SUCCESS® Releases Digital Edition Dedicated to the...](https://www.globenewswire.com/news-release/2026/03/03/3248861/0/en/SUCCESS-Releases-Digital-Edition-Dedicated-to-the-Power-of-Coaching.html "SUCCESS® Releases...")
Next
About Us
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
Global News
- [English](https://www.globenewswire.com/newsroom)
- [Français](https://www.globenewswire.com/fr/newsroom)
- [Deutsch](https://www.globenewswire.com/de/newsroom)
Newswire Distribution Network & Management
- [Home](https://www.globenewswire.com/)
- [Newsroom](https://www.globenewswire.com/newsroom)
- [RSS Feeds](https://www.globenewswire.com/rss/list)
- [Notified](https://www.notified.com/)
- [Legal](https://www.notified.com/privacy)
- [Contact us](https://insight.notified.com/globenewswire-contact-us?utm_medium=Website&utm_source=Contact%20Us&utm_campaign=Contact%20Us%20ENG)
- [Resources](https://www.notified.com/resources)
© 2026 Digital Media Innovations, LLC. All rights reserved.
[GlobeNewswire Linkedin](https://www.linkedin.com/company/1006947 "GlobeNewswire Linkedin") [Notified Twitter](https://twitter.com/Notified "Notified Twitter")
;
[Français](https://www.globenewswire.com/fr/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html) [Deutsch](https://www.globenewswire.com/de/news-release/2026/02/13/3237833/0/en/Novartis-Vanrafia-Phase-III-data-support-slowing-of-kidney-function-decline-in-patients-with-IgA-nephropathy.html)